A071701 Genomically-Guided Treatment Trial in Brain Metastases

Brief description of study

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Brain Metastases,Brain Tumor,Brain Metastases, Brain Tumor
Age: Between 18 Years - 99 Years
Gender: All

Male and Female 18 years of age and older Brain Tumor

Updated on 09 Mar 2024. Study ID: 849264

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).